Intellia Therapeutics (NTLA) News Today $13.23 -0.09 (-0.68%) Closing price 10/29/2026 04:00 PM EasternExtended Trading$12.75 -0.48 (-3.63%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Intellia Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026October 29 at 8:00 AM | globenewswire.comIntellia Therapeutics (NTLA) Projected to Announce Earnings on ThursdayOctober 29 at 3:26 AM | americanbankingnews.comIntellia Therapeutics (NTLA) Set to Release Quarterly Earnings on ThursdayOctober 29 at 3:25 AM | marketbeat.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 28 at 4:15 PM | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head ContrastOctober 23, 2026 | americanbankingnews.comIntellia Therapeutics, Inc. (NTLA) - What Are Researchers Thinking About This Stock?October 22, 2026 | americanbankingnews.com321,274 Shares in Intellia Therapeutics, Inc. $NTLA Bought by Assenagon Asset Management S.A.October 21, 2026 | marketbeat.comIntellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations AdvanceOctober 19, 2026 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $20.72October 17, 2026 | marketbeat.comWells Fargo Keeps Their Hold Rating on Intellia Therapeutics (NTLA)October 16, 2026 | theglobeandmail.comIntellia Therapeutics, Inc. Announces Appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, Effective October 26, 2026October 13, 2026 | marketscreener.comMIntellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsOctober 13, 2026 | rttnews.comIntellia Therapeutics Appoints Jing L. Marantz, M.D.October 13, 2026 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded at BarclaysOctober 8, 2026 | marketbeat.comIntellia Therapeutics Inc (NTLA)October 7, 2026 | in.investing.comIntellia Therapeutics (NASDAQ:NTLA) Stock: Insider Michael Dube Sells 1,864 SharesOctober 7, 2026 | insidertrades.comBarclays Initiates Intellia Therapeutics at Underweight With $8 Price TargetOctober 7, 2026 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 1,864 Shares of StockOctober 6, 2026 | marketbeat.comWells Fargo Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)October 6, 2026 | theglobeandmail.comCathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMDOctober 5, 2026 | msn.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comShort interest alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026October 2, 2026 | msn.comIntellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn!September 27, 2026 | seekingalpha.comIntellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing TherapySeptember 22, 2026 | finance.yahoo.comIntellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)September 10, 2026 | theglobeandmail.comWedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral RatingSeptember 8, 2026 | marketscreener.comMIntellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027September 8, 2026 | rttnews.comCathie Wood’s biotech bet Intellia secured an FDA priority review for rare genetic disorder therapy – retail sees upside in NTLA’s platformSeptember 8, 2026 | msn.comIntellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-zSeptember 8, 2026 | finance.yahoo.comIntellia rises on FDA priority review for one-time hereditary angioedema therapySeptember 8, 2026 | seekingalpha.comIntellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)September 8, 2026 | globenewswire.comIntellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced InSeptember 5, 2026 | finance.yahoo.comIntellia Therapeutics Enters $400 Million OrbiMed Term Loan FacilitySeptember 5, 2026 | finance.yahoo.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comIntellia Secures Up To $400 Mln Non-Dilutive Debt Facility From OrbiMedSeptember 4, 2026 | rttnews.comIntellia Therapeutics, Inc. Secures Non-Dilutive Debt Facility With OrbiMed For Up To $400 MillionSeptember 4, 2026 | marketscreener.comMIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionSeptember 4, 2026 | globenewswire.comIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 4, 2026 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% - Here's What HappenedAugust 19, 2026 | marketbeat.comIntellia (NTLA) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comMorgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)August 12, 2026 | theglobeandmail.comBank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)August 8, 2026 | theglobeandmail.comIntellia upgraded at Evercore ISI on nex-z hypothesisAugust 8, 2026 | seekingalpha.comWill Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative?August 8, 2026 | finance.yahoo.comIntellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comIntellia Therapeutics (NTLA) Q2 2026August 6, 2026 | 247wallst.comIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesAugust 6, 2026 | markets.businessinsider.comIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesJuly 30, 2026 | globenewswire.comIntellia: Phase 3 HAELO Win Doesn't Fix The Commercial ProblemJuly 29, 2026 | seekingalpha.com Intellia Therapeutics Media Mentions By Week Intellia Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.280.66▲Average Healthcare News Sentiment Intellia Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼66▲NTLA Articles Average Week Intellia Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches4-43%Page Views4,392-12% Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Beam Therapeutics News CRISPR Therapeutics News Editas Medicine News Rhythm Pharmaceuticals News Ligand Pharmaceuticals News Kiniksa Pharmaceuticals International News GRAIL News Immunovant News Kodiak Sciences News CG Oncology News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Intellia Therapeutics dated 10/29/2026. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMissed SpaceX’s 1,000% winner? Then this is for you…In 2024, SpaceX began ordering from a tiny supplier called Filtronic. Its stock has since climbed more than 1,...Brownstone Research | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredTrump’s $16 Trillion Chess Move (signed and highlighted)A newly signed executive order could point to one of the largest resource deals in history, according to Matt ...Monument Traders Alliance | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as ...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
